AER 1427865 is a spontaneous case received on 30/Jun/2014 from a physician via company representative and 
concerns a patient of unspecified demographics who developed progressive multifocal leukoencephalopathy while 
being treated with rituximab.
The patient's medical history, concurrent conditions, concomitant drugs or past drugs were not reported
The patients received 4 cycles of rituximab and CHOP (therapy details not reported) for lymphoma. Later, the 
patient experienced progressive multifocal leukoencephalopathy. Action taken with rituximab was not reported.
At the time of this report, the outcome of event (progressive multifocal leukoencephalopathy) was persisting and 
therapy ongoing status of rituximab was not reported.
The reporter did not assess the causality of progressive multifocal leukoencephalopathy with rituximab.
Print Time: 17-MAY-2016 03:39 PM If a field is blank, there is no data for that field Page 619 of 688
FDA - Adverse Event Reporting System (FAERS) 
FOIA Case Report Information
The company assessed progressive multifocal leukoencephalopathy as medically significant. 
No further information was provided.